High LDL cholesterol confers greater risk of ST-segment elevation myocardial infarction than non-ST-segment elevation myocardial infarction in statin-treated patients with ischaemic heart disease
Authors' conclusion
High LDL-C confers greater risk of STEMI than NSTEMI in statin-treated patients with IHD. This is important given the higher early mortality associated with STEMI.
Study context
- Population
- Statin-treated patients with ischaemic heart disease (IHD) determined by coronary angiography from the Western Denmark Heart Registry between 2011 and 202026,178 (71%) men, median age 66 years
- Participants
- 36,739 patients
- Exposure
- Risk of STEMI vs. Non-STEMI (NSTEMI) per 1 mmol/L higher LDL-C
- STEMIn = 531
- NSTEMIn = 1,614reference
- Outcome
- STEMI and NSTEMI risk per 1 mmol/L higher LDL-C
- Follow-up
- Median 4.9 years
Main finding
As reported in the abstract
median follow-up of 4.9 years
Estimate (95% CI)
STEMI
aHR 1.43 per 1 mmol/L higher LDL-C(1.30–1.57)
NSTEMI
aHR 1.23 per 1 mmol/L higher LDL-C(1.16–1.31)
STEMIvs NSTEMI
aOR 1.18 per 1 mmol/L higher LDL-C(1.04–1.33)
Observational data: associations, not effects.
Further findings
| Outcome | aOR (95% CI) | |
|---|---|---|
| 30 day mortality | 1.62 (1.02–2.57) | |
| 0.20.5125Adjusted odds ratio (log scale) |
STEMI and NSTEMI at LDL-C goal ≤1.4 mmol/L vs. >2.2 mmol/L
- Lower risk of STEMI and NSTEMI, with lower odds of STEMI than NSTEMI
- 22% lower odds
non-HDL-C
- Results were similar for non-HDL-C
Original publication
High LDL cholesterol confers greater risk of ST-segment elevation myocardial infarction than non-ST-segment elevation myocardial infarction in statin-treated patients with ischaemic heart disease. Eur Heart J Acute Cardiovasc Care. Published 10 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →